191 related articles for article (PubMed ID: 35562134)
1. Paediatric type diffuse high grade gliomas in the WHO CNS5 classification: What the pathologist needs to know?
Rao S; Sahay A; Epari S
Indian J Pathol Microbiol; 2022 May; 65(Supplement):S50-S58. PubMed ID: 35562134
[TBL] [Abstract][Full Text] [Related]
2. A review of adult-type diffuse gliomas in the WHO CNS5 classification with special reference to Astrocytoma, IDH-mutant and Oligodendroglioma, IDH-mutant and 1p/19q codeleted.
Santosh V; Rao S
Indian J Pathol Microbiol; 2022 May; 65(Supplement):S14-S23. PubMed ID: 35562130
[TBL] [Abstract][Full Text] [Related]
3. 2021 updates to the World Health Organization classification of adult-type and pediatric-type diffuse gliomas: a clinical practice review.
Thomas DL
Chin Clin Oncol; 2023 Feb; 12(1):7. PubMed ID: 36922356
[TBL] [Abstract][Full Text] [Related]
4. Opinion & Special Article: Glioma Classification: How to Interpret Molecular Markers in a Diffuse Glioma Pathology Report.
van der Meulen M; Ramos RC; Mason WP; Von Deimling A; Maas SLN
Neurology; 2022 Nov; 99(20):903-908. PubMed ID: 36240081
[TBL] [Abstract][Full Text] [Related]
5. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
Paul Y; Mondal B; Patil V; Somasundaram K
Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
[TBL] [Abstract][Full Text] [Related]
6. Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors.
Malzkorn B; Reifenberger G
Pathologe; 2019 Jun; 40(Suppl 1):9-17. PubMed ID: 31025086
[TBL] [Abstract][Full Text] [Related]
7. Paediatric-type diffuse high-grade gliomas in the 5th CNS WHO Classification.
Gianno F; Giovannoni I; Cafferata B; Diomedi-Camassei F; Minasi S; Barresi S; Buttarelli FR; Alesi V; Cardoni A; Antonelli M; Puggioni C; Colafati GS; Carai A; Vinci M; Mastronuzzi A; Miele E; Alaggio R; Giangaspero F; Rossi S
Pathologica; 2022 Dec; 114(6):422-435. PubMed ID: 36534421
[TBL] [Abstract][Full Text] [Related]
8. Pediatric-type diffuse low grade gliomas: Histomolecular profile and practical approach to their integrated diagnosis according to the WHO CNS5 classification.
Purkait S; Mahajan S; Sharma MC; Sarkar C; Suri V
Indian J Pathol Microbiol; 2022 May; 65(Supplement):S42-S49. PubMed ID: 35562133
[TBL] [Abstract][Full Text] [Related]
9. [World Health Organization Classification of Central Nervous System Tumours, 5
Ichimura K
No Shinkei Geka; 2023 Mar; 51(2):349-363. PubMed ID: 37055056
[TBL] [Abstract][Full Text] [Related]
10. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
[TBL] [Abstract][Full Text] [Related]
11. Clinical impact of revisions to the WHO classification of diffuse gliomas and associated future problems.
Sonoda Y
Int J Clin Oncol; 2020 Jun; 25(6):1004-1009. PubMed ID: 32020379
[TBL] [Abstract][Full Text] [Related]
12. Updates on the WHO diagnosis of IDH-mutant glioma.
Reuss DE
J Neurooncol; 2023 May; 162(3):461-469. PubMed ID: 36717507
[TBL] [Abstract][Full Text] [Related]
13. Impending Impact of Molecular Pathology on Classifying Adult Diffuse Gliomas.
Macaulay RJ
Cancer Control; 2015 Apr; 22(2):200-5. PubMed ID: 26068765
[TBL] [Abstract][Full Text] [Related]
14. Major Changes in 2021 World Health Organization Classification of Central Nervous System Tumors.
Kurokawa R; Kurokawa M; Baba A; Ota Y; Pinarbasi E; Camelo-Piragua S; Capizzano AA; Liao E; Srinivasan A; Moritani T
Radiographics; 2022; 42(5):1474-1493. PubMed ID: 35802502
[TBL] [Abstract][Full Text] [Related]
15. Adult type diffuse gliomas in the new 2021 WHO Classification.
Antonelli M; Poliani PL
Pathologica; 2022 Dec; 114(6):397-409. PubMed ID: 36534419
[TBL] [Abstract][Full Text] [Related]
16. Diffuse Gliomas for Nonneuropathologists: The New Integrated Molecular Diagnostics.
Lee SC
Arch Pathol Lab Med; 2018 Jul; 142(7):804-814. PubMed ID: 29775073
[TBL] [Abstract][Full Text] [Related]
17. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
[TBL] [Abstract][Full Text] [Related]
18. Reclassification of TCGA Diffuse Glioma Profiles Linked to Transcriptomic, Epigenetic, Genomic and Clinical Data, According to the 2021 WHO CNS Tumor Classification.
Zakharova G; Efimov V; Raevskiy M; Rumiantsev P; Gudkov A; Belogurova-Ovchinnikova O; Sorokin M; Buzdin A
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613601
[TBL] [Abstract][Full Text] [Related]
19. Adult IDH wild-type lower-grade gliomas should be further stratified.
Aibaidula A; Chan AK; Shi Z; Li Y; Zhang R; Yang R; Li KK; Chung NY; Yao Y; Zhou L; Wu J; Chen H; Ng HK
Neuro Oncol; 2017 Oct; 19(10):1327-1337. PubMed ID: 28575485
[TBL] [Abstract][Full Text] [Related]
20. WHO CNS5 2021 classification of gliomas: a practical review and road signs for diagnosing pathologists and proper patho-clinical and neuro-oncological cooperation.
Sejda A; Grajkowska W; Trubicka J; Szutowicz E; Wojdacz T; Kloc W; Iżycka-Świeszewska E
Folia Neuropathol; 2022; 60(2):137-152. PubMed ID: 35950467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]